Julio Cesar Garcia Rodriguez

Julio César García Rodríguez, in 1979, graduated in Biochemistry from Havana University. He obtained the PhD in 2002, the Titular Professor Grade in 2005, and Biotechnologist of Second Level in 2007. He is Titular Professor of the Havana Medical University. He works in the fields of basic Neuroprotection and clinical trial. Fundamentally, his results are in experimental models of stroke using erythropoietin (EPO) as neuroprotectant. He is author of more than 75 scientific publications and several books chapters. He is a pioneer in the use of EPO with low sialic acid content (Neuro-EPO) by nasal way. This new therapeutic approach could revolutionize the treatment of neurodegenerative disorders in the 21st century. He is member of the Society of Neuroscience of Cuba and received three prizes from the Academy of Sciences of Cuba (ACC). Among other distinctions, he has the Order Juan Thomas Roig from ACC and the “San Jorge” Medal from the Academic of Sciences of Ukraine.

1books edited

1chapters authored

Latest work with IntechOpen by Julio Cesar Garcia Rodriguez

Despite significant technological advances in recent years, their impact on our overall health and social, well-being is not always clear to see. Perhaps, one of the best examples of this can be highlighted by the fact that mortality rates as a result of cerebrovascular diseases have hardly changed, if at all. This places cerebrovascular diseases as one of the most prominent causes of both disability and death. In Cuba, for instance, a total of 22,000 cases of cerebrovascular diseases are reported each year in a country where life expectancy should increase to 80 years in the near future. In such a situation, to have a book that includes in a clear and summarized way, a group of topics directly related to the preclinical investigations advances and the therapeutic procedures for the cerebrovascular disease in its acute phase constitutes a useful tool for the wide range of the contributors to this affection's problems solution. In this group is included students, professors, researchers, and health policy makers whose work represents one of the greatest social and human impact challenges of the XXI century basic and clinical neurosciences.

Go to the book